Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Onconetix (ONCO) Asset Writedowns and Impairment (2023 - 2024)

Onconetix (ONCO) has disclosed Asset Writedowns and Impairment for 2 consecutive years, with -$3.2 million as the latest value for Q4 2024.

  • On a quarterly basis, Asset Writedowns and Impairment fell 121.59% to -$3.2 million in Q4 2024 year-over-year; TTM through Dec 2024 was $356637.0, a N/A change, with the full-year FY2024 number at $356637.0, up 33.56% from a year prior.
  • Asset Writedowns and Impairment was -$3.2 million for Q4 2024 at Onconetix, down from $3.2 million in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $14.7 million in Q4 2023 to a low of -$3.2 million in Q4 2024.